• No results found

The inflammable truth of atherosclerosis - Chapter 9: Secukinumab treatment decreases arterial wall inflammation in patients with peripheral spondyloarthritis

N/A
N/A
Protected

Academic year: 2021

Share "The inflammable truth of atherosclerosis - Chapter 9: Secukinumab treatment decreases arterial wall inflammation in patients with peripheral spondyloarthritis"

Copied!
12
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

UvA-DARE (Digital Academic Repository)

The inflammable truth of atherosclerosis

Verweij, S.L.

Publication date

2018

Document Version

Other version

License

Other

Link to publication

Citation for published version (APA):

Verweij, S. L. (2018). The inflammable truth of atherosclerosis.

General rights

It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

(2)

ŚĂƉƚĞƌϵ

Secukinumab treatment decreases

ĂƌƚĞƌŝĂůǁĂůůŝŶŇĂŵŵĂƟŽŶŝŶƉĂƟĞŶƚƐ

ǁŝƚŚƉĞƌŝƉŚĞƌĂůƐƉŽŶĚLJůŽĂƌƚŚƌŝƟƐ

^ŝŵŽŶĞ>͘sĞƌǁĞŝũ͕>ĞŽŶŝĞŬĞ:͘:͘ǀĂŶDĞŶƐ͕ ^ŽƉŚŝĞ:͘ĞƌŶĞůŽƚDŽĞŶƐ͕,ĞŝŶ:͘sĞƌďĞƌŶĞ͕ƌŝŬ^͘'͘^ƚƌŽĞƐ͕ ŽŵŝŶŝƋƵĞ>͘W͘ĂĞƚĞŶ ^ƵďŵŝƩĞĚĂƐƐŚŽƌƚƌĞƉŽƌƚ

(3)

ABSTRACT

KďũĞĐƟǀĞ͗WĂƟĞŶƚƐǁŝƚŚƐƉŽŶĚLJůŽĂƌƚŚƌŝƟƐ;^ƉͿŚĂǀĞŝŶĐƌĞĂƐĞĚĐĂƌĚŝŽǀĂƐĐƵůĂƌƌŝƐŬ͕ƉĂƌƚůLJ ĂƩƌŝďƵƚĞĚƚŽĂƌƚĞƌŝĂůǁĂůůŝŶŇĂŵŵĂƟŽŶ͘tŚĞƌĞĂƐƐĞĐƵŬŝŶƵŵĂď͕ĂŶ/>ϭϳďůŽĐŬĞƌ͕ƐƵĐĐĞƐƐĨƵůůLJ ĂƩĞŶƵĂƚĞƐ ĚŝƐĞĂƐĞ ĂĐƟǀŝƚLJ ŝŶ ^Ɖ͕ ŝƚƐ ĞīĞĐƚ ŽŶ ĂƌƚĞƌŝĂů ǁĂůů ŝŶŇĂŵŵĂƟŽŶ ŝƐ ƵŶŬŶŽǁŶ͘ DĞƚŚŽĚƐ͗ϮϬƉĂƟĞŶƚƐǁŝƚŚƉĞƌŝƉŚĞƌĂů^Ɖ;Ɖ^ƉͿǁĞƌĞƚƌĞĂƚĞĚǁŝƚŚƐĞĐƵŬŝŶƵŵĂď;ϯϬϬŵŐ ǁĞĞŬůLJĚƵƌŝŶŐƚŚĞĮƌƐƚϰǁĞĞŬƐ͕ĨŽůůŽǁĞĚďLJĨŽƵƌͲǁĞĞŬůLJĂĚŵŝŶŝƐƚƌĂƟŽŶƵƉƚŽϭϮǁĞĞŬƐͿ͘ dŚĞZϱϬƌĞƐƉŽŶƐĞĐƌŝƚĞƌŝĂǁĞƌĞƵƐĞĚƚŽĚĞĮŶĞƌĞƐƉŽŶĚĞƌƐƚĂƚƵƐ͘ĂƌŽƟĚĂƌƚĞƌŝĂůǁĂůů ŝŶŇĂŵŵĂƟŽŶǁĂƐĂƐƐĞƐƐĞĚĂƐƚĂƌŐĞƚͲƚŽͲďĂĐŬŐƌŽƵŶĚƌĂƟŽ;dZͿƵƐŝŶŐ18Ͳ&ůƵŽƌŽĚĞŽdžLJŐůƵĐŽƐĞ ƉŽƐŝƚƌŽŶĞŵŝƐƐŝŽŶƚŽŵŽŐƌĂƉŚLJǁŝƚŚĐŽŵƉƵƚĞĚƚŽŵŽŐƌĂƉŚLJ;18&Ͳ&'WdͬdͿĂƚďĂƐĞůŝŶĞĂŶĚ week 12. ZĞƐƵůƚƐ͗ ^ĐĂŶƐ ǁĞƌĞ ĂǀĂŝůĂďůĞ ŝŶ ϭϲ ƉĂƟĞŶƚƐ͘ ^ĞĐƵŬŝŶƵŵĂď ƚƌĞĂƚŵĞŶƚ ƚĞŶĚĞĚ ƚŽ ůŽǁĞƌ dZmean;ϭ͘ϱϬцϬ͘ϯƚŽϭ͘ϰϭцϬ͘Ϯ͖ƉсϬ͘ϬϲϵͿ͘/ŶĂƉŽƐƚͲŚŽĐĂŶĂůLJƐŝƐ͕ƉĂƟĞŶƚƐǁŝƚŚĂŐŽŽĚĐůŝŶŝĐĂů ƌĞƐƉŽŶƐĞ ƐŚŽǁĞĚ Ă ƐŝŐŶŝĮĐĂŶƚ ĚĞĐƌĞĂƐĞ ŝŶ dZ ĂŌĞƌ ƐĞĐƵŬŝŶƵŵĂď ƚƌĞĂƚŵĞŶƚ ;dZmean ϭ͘ϱϬцϬ͘Ϯ ƚŽ ϭ͘ϯϵцϬ͘Ϯ͕ ƉсϬ͘ϬϮϮͿ͕ ǁŚŝůĞ ƚŚĞƌĞ ǁĂƐ ŶŽ ĐŚĂŶŐĞ ŽďƐĞƌǀĞĚ ŝŶ ŶŽŶͲƌĞƐƉŽŶĚĞƌƐ͘

ŽŶĐůƵƐŝŽŶ͗ Secukinumab treatment showed a trend towards a decrease of arterial wall

ŝŶŇĂŵŵĂƟŽŶ ŝŶ Ɖ^Ɖ ƉĂƟĞŶƚƐ͕ ŵĂŝŶůLJ ŝŶ ƉĂƟĞŶƚƐ ǁŝƚŚ Ă ŐŽŽĚ ĐůŝŶŝĐĂů ƌĞƐƉŽŶƐĞ͘ >ĂƌŐĞƌ͕ ĐŽŶƚƌŽůůĞĚƚƌŝĂůƐĂƌĞŶĞĞĚĞĚƚŽĂƐƐĞƐƐƚŚĞƌĞůĂƟŽŶƐŚŝƉǁŝƚŚsĞǀĞŶƚƐ͘

(4)

9

/EdZKhd/KE

^ƉŽŶĚLJůŽĂƌƚŚƌŝƟƐ ;^ƉͿ ŝƐ ĂŶ ŝŵŵƵŶĞͲŵĞĚŝĂƚĞĚ ŝŶŇĂŵŵĂƚŽƌLJ ĚŝƐĞĂƐĞ͕ ǁŝƚŚ ĂŶŬLJůŽƐŝŶŐ ƐƉŽŶĚLJůŝƟƐ ;^Ϳ ĂŶĚ ƉƐŽƌŝĂƟĐ ĂƌƚŚƌŝƟƐ ;WƐͿ ĂƐ ƚŚĞ ŵŽƐƚ ƉƌŽƚŽƚLJƉŝĐĂů ƐƵďͲĨŽƌŵƐ͘ WĂƟĞŶƚƐ ǁŝƚŚ^ƉŚĂǀĞĂŶŝŶĐƌĞĂƐĞĚĐĂƌĚŝŽǀĂƐĐƵůĂƌ;sͿƌŝƐŬ1͕ǁŚŝĐŚŚĂƐďĞĞŶƉĂƌƚůLJĂƩƌŝďƵƚĞĚƚŽƚŚĞ ĐŚƌŽŶŝĐŝŶŇĂŵŵĂƚŽƌLJƐƚĂƚĞŝŶƚŚĞƐĞƉĂƟĞŶƚƐ͘/ŶƐƵƉƉŽƌƚ͕ƉĂƟĞŶƚƐǁŝƚŚWƐĂŶĚ^ǁĞƌĞĨŽƵŶĚ ƚŽŚĂǀĞŝŶĐƌĞĂƐĞĚĂƌƚĞƌŝĂůǁĂůůŝŶŇĂŵŵĂƟŽŶ͕ĂƐƐĞƐƐĞĚǁŝƚŚ18Ͳ&ůƵŽƌŽĚĞŽdžLJŐůƵĐŽƐĞƉŽƐŝƚƌŽŶ ĞŵŝƐƐŝŽŶ ƚŽŵŽŐƌĂƉŚLJ ;18&Ͳ&' WdͬdͿϮ͕ϯ͕ ǁŚŝĐŚ ŝƐ Ă ƉƌĞĚŝĐƚŽƌ ŽĨ ĂĚǀĞƌƐĞ ĐĂƌĚŝŽǀĂƐĐƵůĂƌ

outcome4. 18&Ͳ&'ŝƐĂŐůƵĐŽƐĞĂŶĂůŽŐƵĞ͕ƐŽŝƚƌĞŇĞĐƚƐŵĞƚĂďŽůŝĐĂĐƟǀŝƚLJ͘18&Ͳ&'WdͬdŚĂƐ

ĞŵĞƌŐĞĚ ĂƐ Ă ǀĂůŝĚĂƚĞĚ ŵĞƚŚŽĚ ƚŽ ƋƵĂŶƟĨLJ ĂƌƚĞƌŝĂů ǁĂůů ŝŶŇĂŵŵĂƟŽŶ5͕ ǁŚĞƌĞĂƐ18&Ͳ&' ƵƉƚĂŬĞŝŶƉůĂƋƵĞƐŝƐĂƐƐŽĐŝĂƚĞĚǁŝƚŚŵĂĐƌŽƉŚĂŐĞĐŽŶƚĞŶƚĂŶĚĂĐƟǀŝƚLJ6. />Ͳϭϳ ŚĂƐ ďĞĞŶ ŝĚĞŶƟĮĞĚ ĂƐ Ă ĐƌƵĐŝĂů ŵĞĚŝĂƚŽƌ ŽĨ ƐLJŶŽǀŝĂů ŝŶŇĂŵŵĂƟŽŶ ĂŶĚ ũŽŝŶƚ ĚĞƐƚƌƵĐƟŽŶ ŝŶ ^Ɖ7͘ DŽƌĞ ƌĞĐĞŶƚůLJ͕ />Ͳϭϳ ďůŽĐŬĂĚĞ ƵƐŝŶŐ ƐĞĐƵŬŝŶƵŵĂď ŚĂƐ ďĞĞŶ ŝŶƚƌŽĚƵĐĞĚ ĂƐ ĂŶ ĞīĞĐƟǀĞ ƚŚĞƌĂƉLJ ŝŶ ^Ɖ ƉĂƟĞŶƚƐ8-10͘ ,ŽǁĞǀĞƌ͕ ƚŚĞ ƌŽůĞ ŽĨ />Ͳ ϭϳ ŝŶ ĐĂƌĚŝŽǀĂƐĐƵůĂƌ ĚŝƐĞĂƐĞ ƌĞŵĂŝŶƐ ĐŽŶƚƌŽǀĞƌƐŝĂů͕ ǁŝƚŚ ĚĂƚĂ ƐƵƉƉŽƌƟŶŐ ƉƌŽͲ ĂƐ ǁĞůů ĂƐ ĂŶƟͲĂƚŚĞƌŽŐĞŶŝĐ ĞīĞĐƚƐ ŝŶ ĞdžƉĞƌŝŵĞŶƚĂů ŵŽĚĞůƐ11͘ ŽŶƐĞƋƵĞŶƚůLJ͕ ƚŚĞ ĞīĞĐƚ ŽĨ ĂŶƟͲ/>Ͳϭϳ ƚƌĞĂƚŵĞŶƚ ŽŶ ĂƌƚĞƌŝĂů ǁĂůů ŝŶŇĂŵŵĂƟŽŶ ŝŶ ƉĂƟĞŶƚƐ ŝƐ ƵŶŬŶŽǁŶ͘ dŽĞǀĂůƵĂƚĞƚŚĞĞīĞĐƚŽĨĂŶƟͲ/>ͲϭϳƚŚĞƌĂƉLJŽŶĂƌƚĞƌŝĂůǁĂůůŝŶŇĂŵŵĂƟŽŶŝŶŚƵŵĂŶƐ͕ǁĞ conducted a pilot trial with 18&Ͳ&'WdͲdŝŶ^ƉƉĂƟĞŶƚƐǁŝƚŚƉĞƌŝƉŚĞƌĂůĚŝƐĞĂƐĞ;Ɖ^ƉͿ

ƚƌĞĂƚĞĚǁŝƚŚƐĞĐƵŬŝŶƵŵĂď͕ĂŵŽŶŽĐůŽŶĂůĂŶƟͲ/>ͲϭϳĂŶƟďŽĚLJ͘

DdZ/>^EDd,K^

^ƚƵĚLJƉŽƉƵůĂƟŽŶĂŶĚĚĞƐŝŐŶ dǁĞŶƚLJ ƉĂƟĞŶƚƐ ǁŝƚŚ Ă ĐůŝŶŝĐĂů ĚŝĂŐŶŽƐŝƐ ŽĨ ƉĞƌŝƉŚĞƌĂů ƐƉŽŶĚLJůŽĂƌƚŚƌŝƟƐ͕ ĨƵůĮůůŝŶŐ ƚŚĞ ƐƐĞƐƐŵĞŶƚ ŽĨ ^ƉŽŶĚLJůŽĂƌƚŚƌŝƟƐ /ŶƚĞƌŶĂƟŽŶĂů ^ŽĐŝĞƚLJ ;^^Ϳ ĐůĂƐƐŝĮĐĂƟŽŶ ĐƌŝƚĞƌŝĂ ĨŽƌ ƉĞƌŝƉŚĞƌĂů ƐƉŽŶĚLJůŽĂƌƚŚƌŝƟƐ12͕ ǁĞƌĞ ŝŶĐůƵĚĞĚ ŝŶ Ă ƐŝŶŐůĞͲĐĞŶƚĞƌ͕ ŽƉĞŶ ůĂďĞů͕ ŝŶǀĞƐƟŐĂƚŽƌͲ ŝŶŝƟĂƚĞĚĐůŝŶŝĐĂůƚƌŝĂůǁŝƚŚƐĞĐƵŬŝŶƵŵĂď;ϯϬϬŵŐŽŶĐĞǁĞĞŬůLJĨƌŽŵďĂƐĞůŝŶĞƚŽǁĞĞŬϰĂŶĚ ƚŚĞŶ ĞǀĞƌLJ ϰ ǁĞĞŬƐ ƚŚĞƌĞĂŌĞƌͿ13͘ ůů ƉĂƟĞŶƚƐ ƉƌŽǀŝĚĞĚ ǁƌŝƩĞŶ ŝŶĨŽƌŵĞĚ ĐŽŶƐĞŶƚ ďĞĨŽƌĞ ĞŶƌŽůůŵĞŶƚŝŶƚŚĞƐƚƵĚLJĂƐĂƉƉƌŽǀĞĚďLJƚŚĞƚŚŝĐƐŽŵŵŝƩĞĞŽĨƚŚĞŵƐƚĞƌĚĂŵDĞĚŝĐĂů ĞŶƚĞƌ͘ ůŝŶŝĐĂů ŝŵƉƌŽǀĞŵĞŶƚ ǁĂƐ ŵĞĂƐƵƌĞĚ Ăƚ ǁĞĞŬ ϭϮ ďLJ ƚŚĞ ZϱϬ ƌĞƐƉŽŶƐĞ ĐƌŝƚĞƌŝĂ͕ ǁŚŝĐŚ ĂƌĞĐŽŵŵŽŶůLJ ƵƐĞĚ ŝŶ ƉƐŽƌŝĂƟĐ ĂƌƚŚƌŝƟƐ ĂŶĚ ǁŚŝĐŚ ǁĞƌĞĐĞŶƚůLJ ǀĂůŝĚĂƚĞĚ ĨŽƌ ŶŽŶͲ ƉƐŽƌŝĂƟĐ Ɖ^Ɖ14͘ ĚĚŝƟŽŶĂů ĐůŝŶŝĐĂů ĂŶĚ ůĂďŽƌĂƚŽƌLJ ĂƐƐĞƐƐŵĞŶƚƐ ŝŶĐůƵĚĞĚ ǁĞŝŐŚƚ͕ ŚĞŝŐŚƚ͕ ůŝƉŝĚůĞǀĞůƐ͕^ĂŶĚZWůĞǀĞůƐ͘

(5)

ϭϴ&Ͳ&'WdͬdƐĐĂŶ

dŽŵĞĂƐƵƌĞĂƌƚĞƌŝĂůǁĂůůŝŶŇĂŵŵĂƟŽŶ͕ǁĞƉĞƌĨŽƌŵĞĚ18&Ͳ&'WdͬdŝŵĂŐŝŶŐŽŶĂWŚŝůŝƉƐ

ƐĐĂŶŶĞƌ;WŚŝůŝƉƐ͕ĞƐƚ͕ƚŚĞEĞƚŚĞƌůĂŶĚƐͿĂƚďĂƐĞůŝŶĞĂŶĚĂŌĞƌϭϮǁĞĞŬƐŽĨƚƌĞĂƚŵĞŶƚŝŶϭϴ ƉĂƟĞŶƚƐ͘&ŽƌϮƉĂƟĞŶƚƐ͕ĂWdͬdǁĂƐŶŽƚƉĞƌĨŽƌŵĞĚ͘WĂƟĞŶƚƐǁĞƌĞĨĂƐƚĞĚĨŽƌĂƚůĞĂƐƚϲ hours before infusion of 18&Ͳ&'͘EŝŶĞƚLJŵŝŶƵƚĞƐƉŽƐƚͲŝŶĨƵƐŝŽŶ͕ĂWdƐĐĂŶǁĂƐƉĞƌĨŽƌŵĞĚ

ŝŶĐŽŵďŝŶĂƟŽŶǁŝƚŚĂůŽǁͲĚŽƐĞ͕ŶŽŶͲĐŽŶƚƌĂƐƚĞŶŚĂŶĐĞĚdĨŽƌĂƩĞŶƵĂƟŽŶ͕ĐŽƌƌĞĐƟŽŶĂŶĚ ĂŶĂƚŽŵŝĐĐŽͲƌĞŐŝƐƚƌĂƟŽŶ͘/ŵĂŐĞƐǁĞƌĞĂŶĂůLJnjĞĚǁŝƚŚĚĞĚŝĐĂƚĞĚƐŽŌǁĂƌĞ;KƐŝƌŝy͕'ĞŶĞǀĂ͕ ^ǁŝƚnjĞƌůĂŶĚ͖ŚƩƉ͗ͬͬǁǁǁ͘ŽƐŝƌŝdžͲǀŝĞǁĞƌ͘ĐŽŵͿďLJĞdžƉĞƌŝĞŶĐĞĚƌĞĂĚĞƌƐďůŝŶĚĞĚĨŽƌƉĂƟĞŶƚĚĂƚĂ ĂŶĚƐĞƋƵĞŶĐĞŽĨŝŵĂŐĞƐ͘ƌƚĞƌŝĂů18&Ͳ&'ƵƉƚĂŬĞǁĂƐƋƵĂŶƟĮĞĚďLJĚƌĂǁŝŶŐƌĞŐŝŽŶƐŽĨŝŶƚĞƌĞƐƚ ĂƌŽƵŶĚďŽƚŚĐĂƌŽƟĚƐŽŶϱƐůŝĐĞƐŽĨƚŚĞĐŽͲƌĞŐŝƐƚĞƌĞĚƚƌĂŶƐĂdžŝĂůŝŵĂŐĞƐ͘^ƚĂŶĚĂƌĚŝnjĞĚƵƉƚĂŬĞ ǀĂůƵĞƐ;^hsͿǁĞƌĞĂǀĞƌĂŐĞĚĨŽƌĞĂĐŚĂƌƚĞƌLJ͕ĂŶĚĚŝǀŝĚĞĚďLJƚŚĞĂǀĞƌĂŐĞǀĞŶŽƵƐďĂĐŬŐƌŽƵŶĚ ĂĐƟǀŝƚLJ;^hsmeanͿŝŶƚŚĞũƵŐƵůĂƌǀĞŝŶƚŽŽďƚĂŝŶƚŚĞƚĂƌŐĞƚͲƚŽͲďĂĐŬŐƌŽƵŶĚͲƌĂƟŽ;dZͿ͘dŚĞ^hs ŝƐƚŚĞĚĞĐĂLJͲĐŽƌƌĞĐƚĞĚƟƐƐƵĞĐŽŶĐĞŶƚƌĂƟŽŶŽĨ18&Ͳ&'ŝŶŬƋͬŵů͕ĂĚũƵƐƚĞĚĨŽƌƚŚĞŝŶũĞĐƚĞĚ ĚŽƐĞ͘dŚĞŵĞĂŶĂŶĚŵĂdžŝŵĂůƚĂƌŐĞƚͲƚŽͲďĂĐŬŐƌŽƵŶĚͲƌĂƟŽ;dZmeanĂŶĚdZŵĂdžͿŽĨƚŚĞĐĂƌŽƟĚ

with the highest mean 18&Ͳ&'ƵƉƚĂŬĞǁĞƌĞĚĞƚĞƌŵŝŶĞĚ5.

^ƚĂƟƐƟĐĂůĂŶĂůLJƐŝƐ ůů ĚĂƚĂ ǁĞƌĞ ĂŶĂůLJnjĞĚ ƵƐŝŶŐ ^W^^ ǀĞƌƐŝŽŶ Ϯϯ͘Ϭ ;^W^^ /ŶĐ͕ ŚŝŐĂŐŽ͕ /ůůŝŶŽŝƐͿ͘ ĂƚĂ ĂƌĞ ƉƌĞƐĞŶƚĞĚ ĂƐ ƚŚĞ ŵĞĂŶцƐƚĂŶĚĂƌĚ ĚĞǀŝĂƟŽŶ ;^Ϳ ĨŽƌ ŶŽƌŵĂůůLJ ĚŝƐƚƌŝďƵƚĞĚ ĚĂƚĂ͕ ƚŚĞ ŵĞĚŝĂŶ ǁŝƚŚ ŝŶƚĞƌƋƵĂƌƟůĞ ƌĂŶŐĞ ;/YZͿ ĨŽƌ ŶŽŶͲŶŽƌŵĂůůLJ ĚŝƐƚƌŝďƵƚĞĚ ĚĂƚĂ Žƌ ĂƐ Ă ŶƵŵďĞƌ ;ƉĞƌĐĞŶƚĂŐĞͿĨŽƌĐĂƚĞŐŽƌŝĐĂůǀĂƌŝĂďůĞƐ͘ŝīĞƌĞŶĐĞƐŝŶĐůŝŶŝĐĂůƉĂƌĂŵĞƚĞƌƐĂŶĚdZ͛ƐďĞĨŽƌĞ ĂŶĚĂŌĞƌƚƌĞĂƚŵĞŶƚǁĞƌĞĂƐƐĞƐƐĞĚďLJĂƉĂŝƌĞĚƐƚƵĚĞŶƚ͛ƐdͲƚĞƐƚƐŽƌtŝůĐŽdžŽŶƐŝŐŶĞĚͲƌĂŶŬ ƚĞƐƚ͕ƌĞƐƉĞĐƟǀĞůLJ͕ĨŽƌŶŽƌŵĂůůLJĂŶĚŶŽŶͲŶŽƌŵĂůůLJ ĚŝƐƚƌŝďƵƚĞĚĚĂƚĂ͘/ŶĂƉŽƐƚͲŚŽĐĂŶĂůLJƐŝƐ͕ ĚŝīĞƌĞŶĐĞƐŝŶďĂƐĞůŝŶĞĐŚĂƌĂĐƚĞƌŝƐƟĐƐďĞƚǁĞĞŶƉĂƟĞŶƚƐǁŝƚŚĂŐŽŽĚĐůŝŶŝĐĂůƌĞƐƉŽŶƐĞĂŶĚ ƉĂƟĞŶƚƐǁŝƚŚŶŽĐůŝŶŝĐĂůƌĞƐƉŽŶƐĞǁĞƌĞĂƐƐĞƐƐĞĚďLJĂƐƚƵĚĞŶƚ͛ƐdͲƚĞƐƚŽƌDĂŶŶͲtŚŝƚŶĞLJh ƚĞƐƚĨŽƌ͕ƌĞƐƉĞĐƟǀĞůLJ͕ŶŽƌŵĂůůLJĂŶĚŶŽŶͲŶŽƌŵĂůůLJĚŝƐƚƌŝďƵƚĞĚĚĂƚĂ͘ϮͲƐŝĚĞĚWͲǀĂůƵĞфϬ͘Ϭϱ ǁĂƐĐŽŶƐŝĚĞƌĞĚƐƚĂƟƐƟĐĂůůLJƐŝŐŶŝĮĐĂŶƚ͘

(6)

9

RESULTS

ĂƐĞůŝŶĞĐŚĂƌĂĐƚĞƌŝƐƟĐƐ &ƌŽŵƚŚĞϭϴƉ^ƉƉĂƟĞŶƚƐ͕ϮƉĂƟĞŶƚƐǁĞƌĞĞdžĐůƵĚĞĚĚƵĞƚŽŝŶƐƵĸĐŝĞŶƚŝŵĂŐĞƋƵĂůŝƚLJŽĨ ƚŚĞWdͬd͘ĂƐĞůŝŶĞĐŚĂƌĂĐƚĞƌŝƐƟĐƐŽĨƚŚĞϭϲƉĂƟĞŶƚƐĂƌĞůŝƐƚĞĚŝŶƚĂďůĞϭ͘dǁĞůǀĞƉĂƟĞŶƚƐ ŚĂĚƉƐŽƌŝĂƟĐĂƌƚŚƌŝƟƐĂŶĚϰŶŽŶͲƉƐŽƌŝĂƟĐƉ^Ɖ͕ƉĂƟĞŶƚƐǁĞƌĞϰϱцϭϮLJĞĂƌƐŽůĚ͕ϳϱйŵĂůĞ͕ϳ ƉĂƟĞŶƚƐƵƐĞĚĚŝƐĞĂƐĞͲŵŽĚŝĨLJŝŶŐĂŶƟƌŚĞƵŵĂƟĐĚƌƵŐƐ;DZ͛ƐͿĂƚďĂƐĞůŝŶĞ;ŵĞƚŚŽƚƌĞdžĂƚĞ ;ŶсϮͿ͕ůĞŇƵŶŽŵŝĚĞ;ŶсϮͿ͕ƐƵůĨĂƐĂůĂnjŝŶĞ;ŶсϭͿ͕ƉƌĞĚŶŝƐŽŶ;ŶсϮͿĂŶĚŵĞƐĂůĂnjŝŶĞ;ŶсϭͿͿĂŶĚϲ ƉĂƟĞŶƚƐŚĂĚƵƐĞĚdE&ͲĂŝŶŚŝďŝƚŽƌƐďĞĨŽƌĞŝŶĐůƵƐŝŽŶ͘EŽŶĞŽĨƚŚĞƉĂƟĞŶƚƐŚĂĚĚŝĂďĞƚĞƐŽƌ ŚĂĚĞdžƉĞƌŝĞŶĐĞĚĂƉƌĞǀŝŽƵƐĐĂƌĚŝŽǀĂƐĐƵůĂƌĞǀĞŶƚ͖ƚŚƌĞĞƉĂƟĞŶƚƐƵƐĞĚƐƚĂƟŶƐĂƚďĂƐĞůŝŶĞ͖Ăůů ƉĂƟĞŶƚƐĐŽŶƟŶƵĞĚƐĞĐƵŬŝŶƵŵĂďƚƌĞĂƚŵĞŶƚĂƚƚŚĞƐĂŵĞĚŽƐĞ͘ dĂďůĞϭ͘ĂƐĞůŝŶĞĐŚĂƌĂĐƚĞƌŝƐƟĐƐ ŚĂƌĂĐƚĞƌŝƐƟĐƐ Ɖ^ƉƉĂƟĞŶƚƐ;ŶсϭϲͿ WŽƐƚͲƚƌĞĂƚŵĞŶƚ;ŶсϭϲͿ WǀĂůƵĞ 'ĞŶĚĞƌ͕ŵĞŶͬǁŽŵĞŶ ϭϮͬϰ ŶͬĂ ŶͬĂ ŐĞ͕LJĞĂƌƐ ϰϱцϭϮ ŶͬĂ ŶͬĂ D/͕ŬŐͬŵ2 Ϯϴцϰ ŶͬĂ ŶͬĂ VAS pain score 40[26-51] 15[2-37] 0.002 SJC 3[1.25-4] 0[0-1] 0.001 d: 6[2-9] 1[0-3] фϬ͘ϬϬϭ ZW͕ŵŐͬ> 3.2[1.05-10.50] 1.8[0.9-5.10] 0.023 ^͕ŵŵͬh 11[4-29.50] 6[2-12.50] 0.046 >>ĐŚŽůĞƐƚĞƌŽů͕ŵŵŽůͬ> ϯ͘ϯцϬ͘ϵ ϯ͘ϲцϭ͘Ϭ 0.280 sĂůƵĞƐ ĂƌĞ Ŷ͕ ŵĞĂŶ ц ^ Žƌ ŵĞĚŝĂŶ ΀/YZ΁ ĨŽƌ ŶŽŶͲŶŽƌŵĂůůLJ ĚŝƐƚƌŝďƵƚĞĚ ĚĂƚĂ͘ D/ ŝŶĚŝĐĂƚĞƐ ďŽĚLJ ŵĂƐƐ ŝŶĚĞdž͕ ZW͖ͲƌĞĂĐƟǀĞƉƌŽƚĞŝŶ͕^:͖ƐǁŽůůĞŶũŽŝŶƚĐŽƵŶƚ͕d:͖ƚĞŶĚĞƌũŽŝŶƚĐŽƵŶƚ͕s^͖ǀŝƐƵĂůĂŶĂůŽŐƵĞƐĐĂůĞ ůŝŶŝĐĂůƌĞƐƉŽŶƐĞ ŝŐŚƚŽĨƚŚĞϭϲƉĂƟĞŶƚƐǁĞƌĞĐůĂƐƐŝĮĞĚĂƐĐůŝŶŝĐĂůƌĞƐƉŽŶĚĞƌƐ;ZϱϬĂĐŚŝĞǀĞĚͿ͕ǁŝƚŚďĂƐĞůŝŶĞ ĐŚĂƌĂĐƚĞƌŝƐƟĐƐďĞŝŶŐĐŽŵƉĂƌĂďůĞďĞƚǁĞĞŶƚŚĞƌĞƐƉŽŶĚĞƌƐĂŶĚŶŽŶͲƌĞƐƉŽŶĚĞƌƐ;ƚĂďůĞ^ϭͿ͘ ZϱϬƌĞƐƉŽŶĚĞƌƐƐŚŽǁĞĚĂƐŝŐŶŝĮĐĂŶƚĚĞĐƌĞĂƐĞŽĨƉĞƌŝƉŚĞƌĂůĚŝƐĞĂƐĞĂĐƟǀŝƚLJĂŶĚƐLJƐƚĞŵŝĐ ŝŶŇĂŵŵĂƟŽŶ ;ZWͿ ĂŌĞƌ ƚƌĞĂƚŵĞŶƚ͕ ǁŚŝůĞ ŽŶůLJ Ă ĚĞĐƌĞĂƐĞ ŝŶ ƉĞƌŝƉŚĞƌĂů ĚŝƐĞĂƐĞ ĂĐƟǀŝƚLJ ;ƐǁŽůůĞŶĂŶĚƚĞŶĚĞƌũŽŝŶƚĐŽƵŶƚƐͿǁĂƐƐŚŽǁŶŝŶŶŽŶͲƌĞƐƉŽŶĚĞƌƐ;ƚĂďůĞ^ϭͿ͘

(7)

/ŵƉĂĐƚŽŶĂƌƚĞƌŝĂůǁĂůůŝŶŇĂŵŵĂƟŽŶ

/Ŷ ƚŚĞ ǁŚŽůĞ ŐƌŽƵƉ͕ ƐĞĐƵŬŝŶƵŵĂď ƚƌĞĂƚŵĞŶƚ ƌĞƐƵůƚĞĚ ŝŶ Ă ƚƌĞŶĚ ƚŽǁĂƌĚƐ Ă dZ ĚĞĐƌĞĂƐĞ between baseline and week 12: 18&Ͳ&'ƵƉƚĂŬĞŝŶƚŚĞĐĂƌŽƟĚƐǁĂƐƌĞĚƵĐĞĚďLJϲй;dZ

mean ϭ͘ϱϬцϬ͘ϯƚŽϭ͘ϰϭцϬ͘Ϯ͕ƉсϬ͘Ϭϲϵ͖dZŵĂdžϭ͘ϴϰцϬ͘ϰƚŽϭ͘ϳϯцϬ͘ϯ͕ƉсϬ͘Ϭϴϭ͖ƚĂďůĞϮͿ͘dŚĞƌĞǁĂƐŶŽ ĐŚĂŶŐĞŝŶůŝƉŝĚůĞǀĞůƐ;ƚĂďůĞϭͿ͘ /Ŷ Ă ƉŽƐƚͲŚŽĐ ĂŶĂůLJƐŝƐ͕ ĐŽŵƉĂƌŝŶŐ dZ ĐŚĂŶŐĞ ǁŝƚŚŝŶ ZϱϬ ƌĞƐƉŽŶĚĞƌƐ ĂŶĚ ǁŝƚŚŝŶ ŶŽŶͲ ƌĞƐƉŽŶĚĞƌƐ͕ ŽŶůLJ ƌĞƐƉŽŶĚĞƌƐ ƐŚŽǁĞĚ Ă ƐŝŐŶŝĮĐĂŶƚ ĚĞĐƌĞĂƐĞ ŝŶ dZ ĂŌĞƌ ƐĞĐƵŬŝŶƵŵĂď ƚƌĞĂƚŵĞŶƚ ;dZmean ϭ͘ϱϬцϬ͘Ϯ ƚŽ ϭ͘ϯϵцϬ͘Ϯ͕ ƉсϬ͘ϬϮϮ͖ dZŵĂdž ϭ͘ϴϳцϬ͘ϰ ƚŽ ϭ͘ϳϰцϬ͘ϰ͕ ƉсϬ͘ϬϯϮ͖ ƚĂďůĞϮͿ͕ǁŚĞƌĞĂƐŶŽĐŚĂŶŐĞǁĂƐŽďƐĞƌǀĞĚŝŶƚŚĞŶŽŶͲƌĞƐƉŽŶĚĞƌƐ͘ dĂďůĞϮ͘dŚĞĞīĞĐƚŽĨƐĞĐƵŬŝŶƵŵĂďƚƌĞĂƚŵĞŶƚŽŶĂƌƚĞƌŝĂůǁĂůůŝŶŇĂŵŵĂƟŽŶĚŝƐƉůĂLJĞĚĂƐĐŽŚŽƌƚĂŶĚƉĞƌ

responder and non-responder group

dZďĂƐĞůŝŶĞ dZǁŬϭϮ ƉͲǀĂůƵĞ Whole cohort dZ mean ϭ͘ϱϬцϬ͘ϯ ϭ͘ϰϭцϬ͘Ϯ 0.069 ;ŶсϭϲͿ dZ ŵĂdž ϭ͘ϴϰцϬ͘ϰ ϭ͘ϳϯцϬ͘ϯ 0.081 ZĞƐƉŽŶĚĞƌƐ dZ mean ϭ͘ϱϬцϬ͘Ϯ ϭ͘ϯϵцϬ͘Ϯ 0.022 ;ŶсϴͿ dZ ŵĂdž ϭ͘ϴϳцϬ͘ϰ ϭ͘ϳϰцϬ͘ϰ 0.032 Non-responders dZ mean ϭ͘ϰϵцϬ͘ϯ ϭ͘ϰϮцϬ͘Ϯ 0.460 ;ŶсϴͿ dZ ŵĂdž ϭ͘ϴϭцϬ͘ϱ ϭ͘ϳϯцϬ͘ϯ 0.462 sĂůƵĞƐĂƌĞŵĞĂŶц^͘dZŝŶĚŝĐĂƚĞƐƚĂƌŐĞƚͲƚŽͲďĂĐŬŐƌŽƵŶĚƌĂƟŽ͕ŵĂdž͗ŵĂdžŝŵƵŵ

(8)

9

/^h^^/KE

dŚĞƉƌĞƐĞŶƚƐƚƵĚLJƐŚŽǁĞĚĂƚƌĞŶĚƚŽǁĂƌĚƐĚĞĐƌĞĂƐĞĚĂƌƚĞƌŝĂůǁĂůůŝŶŇĂŵŵĂƟŽŶŝŶƉ^Ɖ ƉĂƟĞŶƚƐƵƉŽŶϭϮͲǁĞĞŬƚƌĞĂƚŵĞŶƚǁŝƚŚƐĞĐƵŬŝŶƵŵĂď͘/ŶĂƉŽƐƚͲŚŽĐĂŶĂůLJƐŝƐ͕Ɖ^ƉƉĂƟĞŶƚƐ ǁŝƚŚ ĂŐŽŽĚ ĐůŝŶŝĐĂů ƌĞƐƉŽŶƐĞ ƐŚŽǁĞĚĂƐŝŐŶŝĮĐĂŶƚĚĞĐůŝŶĞ ŝŶ dZ ĨŽůůŽǁŝŶŐ ƐĞĐƵŬŝŶƵŵĂď ƚƌĞĂƚŵĞŶƚ͕ ǁŚĞƌĞĂƐ ŝŶ ŶŽŶͲƌĞƐƉŽŶĚĞƌƐ ŶŽ ĐŚĂŶŐĞ ƵƉŽŶ ƐĞĐƵŬŝŶƵŵĂď ƚƌĞĂƚŵĞŶƚ ǁĂƐ observed. WĂƟĞŶƚƐ ǁŝƚŚ ^Ɖ͕ ƐŝŵŝůĂƌ ƚŽ ƉĂƟĞŶƚƐ ǁŝƚŚ ƌŚĞƵŵĂƚŽŝĚ ĂƌƚŚƌŝƟƐ2͕ ĂƌĞ ĐŚĂƌĂĐƚĞƌŝnjĞĚ ďLJ ĂŶ ŝŶĐƌĞĂƐĞĚĂƌƚĞƌŝĂůǁĂůůŝŶŇĂŵŵĂƟŽŶĐŽŵƉĂƌĞĚǁŝƚŚŚĞĂůƚŚLJĐŽŶƚƌŽůƐ3͕ǁŚŝĐŚŝƐĂƉƌĞĚŝĐƚŽƌ

for adverse cardiovascular outcome4͘dƌĞĂƚŵĞŶƚǁŝƚŚĂŶƟͲŝŶŇĂŵŵĂƚŽƌLJƚŚĞƌĂƉŝĞƐƐƵĐŚĂƐ

dE&ͲĂŝŶŚŝďŝƚŽƌƐĂŶĚŵĞƚŚŽƚƌĞdžĂƚĞŝŶƉĂƟĞŶƚƐǁŝƚŚ^ƉĂŶĚƌŚĞƵŵĂƚŽŝĚĂƌƚŚƌŝƟƐŚĂƐďĞĞŶ shown to reduce CV risk15͘dƌĞĂƚŵĞŶƚǁŝƚŚdE&ͲĂŝŶŚŝďŝƚŽƌƐĂůƐŽĚŝƐƉůĂLJĞĚĂƌĞĚƵĐƟŽŶŽĨ

ĚŝƐĞĂƐĞĂĐƟǀŝƚLJĂŶĚĂƌƚĞƌŝĂůǁĂůůŝŶŇĂŵŵĂƟŽŶŝŶƉĂƟĞŶƚƐǁŝƚŚWƐ16 as well as rheumatoid ĂƌƚŚƌŝƟƐƉĂƟĞŶƚƐ17͕ƐƵƉƉŽƌƟŶŐĂĐŽŵŵŽŶƉĂƚŚŽƉŚLJƐŝŽůŽŐŝĐĂůŵĞĐŚĂŶŝƐŵĨŽƌƚŚĞŝŶĐƌĞĂƐĞĚ ĂƌƚĞƌŝĂůǁĂůůŝŶŇĂŵŵĂƟŽŶĂŶĚŝŶĐƌĞĂƐĞĚsƌŝƐŬ͘/Ŷ^ƉƉĂƟĞŶƚƐ͕ƚŚĞ/>ͲϭϳĂdžŝƐŚĂƐƉƌŽǀĞŶ ƚŽďĞŝŶƐƚƌƵŵĞŶƚĂůŝŶƚŚĞƉĂƚŚŽŐĞŶĞƐŝƐŽĨĂƌƟĐƵůĂƌĚŝƐĞĂƐĞ7͕ŚŽǁĞǀĞƌƚŚĞƉŽƚĞŶƟĂůĞīĞĐƚŽĨ />ͲϭϳŝŶŚŝďŝƟŽŶŽŶĂƚŚĞƌŽƐĐůĞƌŽƐŝƐƌĞŵĂŝŶƐĞƋƵŝǀŽĐĂůĂƐĐŽŶŇŝĐƟŶŐĚĂƚĂĞdžŝƐƚƐŽŶ/>Ͳϭϳ ŵĞĚŝĂƚĞĚĐŚĂŶŐĞƐŝŶƚŚĞĂƌƚĞƌŝĂůǁĂůů͘KŶŽŶĞŚĂŶĚ͕/>ͲϭϳŚĂƐďĞĞŶƐŚŽǁŶƚŽƐƵƉƉŽƌƚƚŚĞ ƉƌŽĚƵĐƟŽŶŽĨƉƌŽͲŝŶŇĂŵŵĂƚŽƌLJŵĞĚŝĂƚŽƌƐ͕ĂŐŐƌĂǀĂƟŶŐŝŶŇĂŵŵĂƚŽƌLJĂĐƟǀŝƚLJŝŶƚŚĞĂƌƚĞƌŝĂů wallϭϴ͕ϭϵ͘ KŶ ƚŚĞ ŽƚŚĞƌ ŚĂŶĚ͕ />Ͳϭϳ ŵĂLJ ĞŶŚĂŶĐĞ ƉůĂƋƵĞ ƐƚĂďŝůŝƚLJ ďLJ ƉƌŽŵŽƟŶŐ ĐŽůůĂŐĞŶ ƉƌŽĚƵĐƟŽŶ20͘DŽƌĞŽǀĞƌ͕/>ͲϭϳŝŶŚŝďŝƚƐsDͲϭĞdžƉƌĞƐƐŝŽŶŽŶĞŶĚŽƚŚĞůŝĂůĐĞůůƐ͕ƌĞĚƵĐŝŶŐ ĂĚŚĞƐŝŽŶŽĨŝŵŵƵŶĞĐĞůůƐƚŽƚŚĞĞŶĚŽƚŚĞůŝĂůůĂLJĞƌ21͘dŚĞƉƌĞƐĞŶƚƐƚƵĚLJƐƵƉƉŽƌƚƐĂŶŽǀĞƌĂůů ĂƚŚĞƌŽƉƌŽƚĞĐƟǀĞĞīĞĐƚŽĨ/>ͲϭϳŝŶŚŝďŝƟŽŶ͗ǁĞƌĞƉŽƌƚĂƚƌĞŶĚƚŽǁĂƌĚƐĚĞĐƌĞĂƐĞŽĨĂƌƚĞƌŝĂů ǁĂůůŝŶŇĂŵŵĂƟŽŶƵƉŽŶƐĞĐƵŬŝŶƵŵĂďƚƌĞĂƚŵĞŶƚ͕ĞƐƉĞĐŝĂůůLJŝŶƉ^ƉƉĂƟĞŶƚƐǁŝƚŚĂŐŽŽĚ ĐůŝŶŝĐĂů ƌĞƐƉŽŶƐĞ͘ KƵƌ ĚĂƚĂ ĂƌĞ ĐŽŶƐŝƐƚĞŶƚ ǁŝƚŚ ƚŚĞ ƉŽƐŝƟǀĞ ĞīĞĐƚ ŽĨ dE&ͲĂ ŝŶŚŝďŝƚŽƌƐ ŽŶ ĂƌƚĞƌŝĂůǁĂůůŝŶŇĂŵŵĂƟŽŶ16. dŚĞƌĞ ĂƌĞ ƐĞǀĞƌĂů ůŝŵŝƚĂƟŽŶƐ ƚŽ ƚŚĞ ƉƌĞƐĞŶƚ ƐƚƵĚLJ͘ &ŝƌƐƚ͕Ă ƐĂŵƉůĞ ƐŝnjĞŽĨ ϭϲ ƉĂƟĞŶƚƐ ŚĂƐ ďĞĞŶƉƌŽǀĞŶƚŽďĞŽĨƐƵĸĐŝĞŶƚƐŝnjĞƚŽĂŶƐǁĞƌŽƵƌŵĂŝŶƌĞƐĞĂƌĐŚƋƵĞƐƟŽŶ͘,ŽǁĞǀĞƌ͕ƚŚĞ ƐŵĂůů ƐĂŵƉůĞ ƐŝnjĞ ĚŽĞƐ ůŝŵŝƚ ƚŚĞ ƉŽƐƐŝďŝůŝƟĞƐ ĨŽƌ ƚŚĞ ƉŽƐƚͲŚŽĐ ĂŶĂůLJƐŝƐ ǁŝƚŚŝŶ ƚŚŝƐ ĐŽŚŽƌƚ͘ dŚĞƌĞĨŽƌĞ͕ǁĞŽŶůLJĂƐƐĞƐƐĞĚƚŚĞdZĚŝīĞƌĞŶĐĞǁŝƚŚŝŶƚŚĞƌĞƐƉŽŶĚĞƌĂŶĚŶŽŶͲƌĞƐƉŽŶĚĞƌ ŐƌŽƵƉƐ ĂŶĚ ŶŽƚ ďĞƚǁĞĞŶ ƚŚĞ Ϯ ŐƌŽƵƉƐ͘ ^ĞĐŽŶĚ͕ ƚŚŝƐ ƉŝůŽƚ ƐƚƵĚLJ ŝƐ ĂŶ ŽƉĞŶͲůĂďĞů ƐƚƵĚLJ͕ ƉƌĞĐůƵĚŝŶŐĂĚŝƌĞĐƚĐŽŵƉĂƌŝƐŽŶǁŝƚŚŶŽŶͲƚƌĞĂƚĞĚĐŽŶƚƌŽůƐ͘>ĂƐƚůLJ͕ƚŚŝƐƉŝůŽƚƐƚƵĚLJĐŽǀĞƌƐŽŶůLJ ϭϮǁĞĞŬƐ͕ǁŚŝĐŚŝƐŶŽƚůŽŶŐĞŶŽƵŐŚƚŽĂƐƐĞƐƐƚŚĞƉŽƚĞŶƟĂůƌĞůĂƟŽŶƐŚŝƉďĞƚǁĞĞŶƚŚĞĞīĞĐƚ ŽĨƐĞĐƵŬŝŶƵŵĂďŽŶĂƌƚĞƌŝĂůǁĂůůŝŶŇĂŵŵĂƟŽŶĂŶĚsĞǀĞŶƚƐ͘,ŽǁĞǀĞƌ͕ƐŝŶĐĞƚŚĞĞīĞĐƚŽŶ ĂƌƚĞƌŝĂůǁĂůůŝŶŇĂŵŵĂƟŽŶŝƐƚŚĞƉƌŝŵĂƌLJŽƵƚĐŽŵĞŽĨƚŚŝƐƐƚƵĚLJ͕ϯŵŽŶƚŚƐƚƌĞĂƚŵĞŶƚƐŚŽƵůĚ ďĞƐƵĸĐŝĞŶƚƚŽƐŚŽǁĞīĞĐƚŽŶĂƌƚĞƌŝĂůǁĂůůŝŶŇĂŵŵĂƟŽŶ͕ĂƐƚƌĞĂƚŵĞŶƚǁŝƚŚdE&ͲĂŝŶŚŝďŝƚŽƌƐ

(9)

ĨŽƌŽŶůLJϴǁĞĞŬƐǁĂƐĂĚĞƋƵĂƚĞƚŽĚŝƐƉůĂLJƌĞĚƵĐƟŽŶŽĨĂƌƚĞƌŝĂůǁĂůůŝŶŇĂŵŵĂƟŽŶŝŶƉĂƟĞŶƚƐ ǁŝƚŚƌŚĞƵŵĂƚŽŝĚĂƌƚŚƌŝƟƐ17. /ŶĐŽŶĐůƵƐŝŽŶ͕ƚŚŝƐƉŝůŽƚƐƚƵĚLJŝŶƉ^ƉƉĂƟĞŶƚƐƐŚŽǁĞĚƚŚĂƚƚƌĞĂƚŵĞŶƚǁŝƚŚƐĞĐƵŬŝŶƵŵĂď ƌĞƐƵůƚĞĚ ŝŶ Ă ƚƌĞŶĚ ƚŽǁĂƌĚƐ ĚĞĐƌĞĂƐĞ ŽĨ ĂƌƚĞƌŝĂů ǁĂůů ŝŶŇĂŵŵĂƟŽŶ͕ ŵĂŝŶůLJ ŝŶ ƉĂƟĞŶƚƐ Ă ŐŽŽĚĐůŝŶŝĐĂůƌĞƐƉŽŶƐĞƚŽƐĞĐƵŬŝŶƵŵĂď͘>ĂƌŐĞƌ͕ĐŽŶƚƌŽůůĞĚƚƌŝĂůƐĂƌĞŶĞĞĚĞĚƚŽĐŽŶĮƌŵƚŚĞƐĞ ĮŶĚŝŶŐƐĂŶĚƚŽĂƐƐĞƐƐƚŚĞƌĞůĂƟŽŶƐŚŝƉǁŝƚŚsĞǀĞŶƚƐ͘ ĐŬŶŽǁůĞĚŐĞŵĞŶƚƐ dŚĞĂƵƚŚŽƌƐƚŚĂŶŬD͘&͘>Ăŵ͕D͘͘,ĞŵĂLJĂƚĂŶĚ͘WŽĞůĨŽƌƉĞƌĨŽƌŵŝŶŐWdͬdƐĐĂŶƐ͘ ŽŵƉĞƟŶŐŝŶƚĞƌĞƐƚƐ ŽŵŝŶŝƋƵĞ ĂĞƚĞŶ ƌĞĐĞŝǀĞĚ ƵŶƌĞƐƚƌŝĐƚĞĚ ŐƌĂŶƚƐ ĨƌŽŵ ďďsŝĞ͕ WĮnjĞƌ͕ h͕ D^͕ :ĂŶƐƐĞŶ͕ EŽǀĂƌƟƐ͕ ůŝ >ŝůůLJ͕ ĂŶĚ ŽĞŚƌŝŶŐĞƌ /ŶŐĞůŚĞŝŵ͘ ŽŵŝŶŝƋƵĞ ĂĞƚĞŶ ŝƐ ƉĂƌƚͲƟŵĞ ĞŵƉůŽLJĞĞ ŽĨ h͘ dŚĞ ŝŶƐƟƚƵƟŽŶ ŚĂƐ ƌĞĐĞŝǀĞĚ ƐƉĞĂŬĞƌƐ ĨĞĞ ĨŽƌ ƌŝŬ ^ƚƌŽĞƐ ĨƌŽŵ ŵŐĞŶ͕ ^ĂŶŽĮ͕ ZĞŐĞŶĞƌŽŶ͕/ŽŶŝƐ͕ŬĐĞĂĂŶĚEŽǀĂƌƟƐ͘EŽŶĞŽĨƚŚĞŽƚŚĞƌĂƵƚŚŽƌƐŚĂǀĞĚŝƐĐůŽƐƵƌĞƐ͘ &ƵŶĚŝŶŐ dŚŝƐ ƉƌŽũĞĐƚŚĂƐ ƌĞĐĞŝǀĞĚ ĨƵŶĚŝŶŐĨƌŽŵ ƚŚĞ ƵƌŽƉĞĂŶ hŶŝŽŶ͛Ɛ ,ŽƌŝnjŽŶ ϮϬϮϬƌĞƐĞĂƌĐŚ ĂŶĚ ŝŶŶŽǀĂƟŽŶƉƌŽŐƌĂŵƵŶĚĞƌŐƌĂŶƚĂŐƌĞĞŵĞŶƚEŽϲϲϳϴϯϳ͟ĂŶĚĨƌŽŵƵŶƌĞƐƚƌŝĐƚĞĚŐƌĂŶƚƐĨƌŽŵ EŽǀĂƌƟƐ͕Ăs//'ƌĂŶƚŽĨƚŚĞEĞƚŚĞƌůĂŶĚƐKƌŐĂŶŝnjĂƟŽŶĨŽƌ^ĐŝĞŶƟĮĐZĞƐĞĂƌĐŚ;EtKͿĂŶĚĂ ŽŶƐŽůŝĚĂƚŽƌ'ƌĂŶƚŽĨƚŚĞƵƌŽƉĞĂŶZĞƐĞĂƌĐŚŽƵŶĐŝů;ZͿ͘

(10)

9

ZĞĨĞƌĞŶĐĞƐ

ϭ͘ DĂƚŚŝĞƵ^͕WĞƌĞŝƌĂ͕^ŽƵďƌŝĞƌD͘ĂƌĚŝŽǀĂƐ- ĐƵůĂƌĞǀĞŶƚƐŝŶĂŶŬLJůŽƐŝŶŐƐƉŽŶĚLJůŝƟƐ͗ĂŶƵƉ-ĚĂƚĞĚŵĞƚĂͲĂŶĂůLJƐŝƐ͘^ĞŵŝŶƌƚŚƌŝƟƐZŚĞƵŵ͘ ϮϬϭϱ͖ϰϰ;ϱͿ͗ϱϱϭͲϱϱϱ͘ Ϯ͘ ZŽƐĞ^͕^ŚĞƚŚE,͕ĂŬĞƌ:&ĞƚĂů͘ĐŽŵƉĂƌ-ŝƐŽŶŽĨǀĂƐĐƵůĂƌŝŶŇĂŵŵĂƟŽŶŝŶƉƐŽƌŝĂƐŝƐ͕ ƌŚĞƵŵĂƚŽŝĚĂƌƚŚƌŝƟƐ͕ĂŶĚŚĞĂůƚŚLJƐƵďũĞĐƚƐďLJ &'ͲWdͬd͗ĂƉŝůŽƚƐƚƵĚLJ͘Am J Cardiovasc Dis. ϮϬϭϯ͖ϯ;ϰͿ͗ϮϳϯͲϮϳϴ͘ ϯ͘ ǀĂŶĚĞƌsĂůŬ&D͕ĞƌŶĞůŽƚDŽĞŶƐ^:͕sĞƌǁĞŝũ ^>ĞƚĂů͘/ŶĐƌĞĂƐĞĚĂƌƚĞƌŝĂůǁĂůůŝŶŇĂŵŵĂƟŽŶ ŝŶƉĂƟĞŶƚƐǁŝƚŚĂŶŬLJůŽƐŝŶŐƐƉŽŶĚLJůŝƟƐŝƐ ƌĞĚƵĐĞĚďLJƐƚĂƟŶƚŚĞƌĂƉLJ͘Ann Rheum Dis. ϮϬϭϲ͖ϳϱ;ϭϬͿ͗ϭϴϰϴͲϭϴϱϭ͘

ϰ͘ &ŝŐƵĞƌŽĂ>͕ďĚĞůďĂŬLJ͕dƌƵŽŶŐYĞƚĂů͘ DĞĂƐƵƌĞŵĞŶƚŽĨĂƌƚĞƌŝĂůĂĐƟǀŝƚLJŽŶƌŽƵƟŶĞ &'WdͬdŝŵĂŐĞƐŝŵƉƌŽǀĞƐƉƌĞĚŝĐƟŽŶŽĨ risk of future CV events. JACC Cardiovasc

Imaging. ϮϬϭϯ͖ϲ;ϭϮͿ͗ϭϮϱϬͲϭϮϱϵ͘ ϱ͘ ZƵĚĚ:,͕DLJĞƌƐ<^͕ĂŶƐŝůĂů^ĞƚĂů͘;ϭϴͿ &ůƵŽƌŽĚĞŽdžLJŐůƵĐŽƐĞƉŽƐŝƚƌŽŶĞŵŝƐƐŝŽŶƚŽ-ŵŽŐƌĂƉŚLJŝŵĂŐŝŶŐŽĨĂƚŚĞƌŽƐĐůĞƌŽƟĐƉůĂƋƵĞ ŝŶŇĂŵŵĂƟŽŶŝƐŚŝŐŚůLJƌĞƉƌŽĚƵĐŝďůĞ͗ŝŵƉůŝĐĂ-ƟŽŶƐĨŽƌĂƚŚĞƌŽƐĐůĞƌŽƐŝƐƚŚĞƌĂƉLJƚƌŝĂůƐ͘J Am Coll Cardiol. ϮϬϬϳ͖ϱϬ;ϵͿ͗ϴϵϮͲϴϵϲ͘ ϲ͘ 'ƌĂĞďĞD͕WĞĚĞƌƐĞŶ^&͕ŽƌŐǁĂƌĚƚ>ĞƚĂů͘ DŽůĞĐƵůĂƌƉĂƚŚŽůŽŐLJŝŶǀƵůŶĞƌĂďůĞĐĂƌŽƟĚ ƉůĂƋƵĞƐ͗ĐŽƌƌĞůĂƟŽŶǁŝƚŚ΀ϭϴ΁ͲŇƵŽƌŽĚĞ- ŽdžLJŐůƵĐŽƐĞƉŽƐŝƚƌŽŶĞŵŝƐƐŝŽŶƚŽŵŽŐƌĂ-ƉŚLJ;&'ͲWdͿ͘Eur J Vasc Endovasc Surg. ϮϬϬϵ͖ϯϳ;ϲͿ͗ϳϭϰͲϳϮϭ͘ ϳ͘ ZĂLJĐŚĂƵĚŚƵƌŝ^W͕ZĂLJĐŚĂƵĚŚƵƌŝ^<͘DĞĐŚĂ-ŶŝƐƟĐƌĂƟŽŶĂůĞƐĨŽƌƚĂƌŐĞƟŶŐŝŶƚĞƌůĞƵŬŝŶͲϭϳ ŝŶƐƉŽŶĚLJůŽĂƌƚŚƌŝƟƐ͘ƌƚŚƌŝƟƐZĞƐdŚĞƌ͘ ϮϬϭϳ͖ϭϵ;ϭͿ͗ϱϭ͘ ϴ͘ ĂĞƚĞŶ͕^ŝĞƉĞƌ:͕ƌĂƵŶ:ĞƚĂů͘^ĞĐƵŬŝŶƵŵ-Ăď͕ĂŶ/ŶƚĞƌůĞƵŬŝŶͲϭϳ/ŶŚŝďŝƚŽƌ͕ŝŶŶŬLJůŽƐŝŶŐ ^ƉŽŶĚLJůŝƟƐ͘N Engl J Med. ϮϬϭϱ͖ϯϳϯ;ϮϲͿ͗ϮϱϯϰͲ 2548. ϵ͘ DĞĂƐĞW:͕DĐ/ŶŶĞƐ/͕<ŝƌŬŚĂŵĞƚĂů͘ ^ĞĐƵŬŝŶƵŵĂď/ŶŚŝďŝƟŽŶŽĨ/ŶƚĞƌůĞƵŬŝŶͲϭϳŝŶ WĂƟĞŶƚƐǁŝƚŚWƐŽƌŝĂƟĐƌƚŚƌŝƟƐ͘N Engl J Med. ϮϬϭϱ͖ϯϳϯ;ϭϰͿ͗ϭϯϮϵͲϭϯϯϵ͘ ϭϬ͘ DĐ/ŶŶĞƐ/͕DĞĂƐĞW:͕<ŝƌŬŚĂŵĞƚĂů͘ ^ĞĐƵŬŝŶƵŵĂď͕ĂŚƵŵĂŶĂŶƟͲŝŶƚĞƌůĞƵŬŝŶͲϭϳ ŵŽŶŽĐůŽŶĂůĂŶƟďŽĚLJ͕ŝŶƉĂƟĞŶƚƐǁŝƚŚ ƉƐŽƌŝĂƟĐĂƌƚŚƌŝƟƐ;&hdhZϮͿ͗ĂƌĂŶĚŽŵŝƐĞĚ͕ ĚŽƵďůĞͲďůŝŶĚ͕ƉůĂĐĞďŽͲĐŽŶƚƌŽůůĞĚ͕ƉŚĂƐĞϯ trial. Lancet. ϮϬϭϱ͖ϯϴϲ;ϵϵϵϵͿ͗ϭϭϯϳͲϭϭϰϲ͘ ϭϭ͘ 'ŽŶŐ&͕>ŝƵ͕>ŝƵ:ĞƚĂů͘dŚĞƉĂƌĂĚŽdžŝĐĂůƌŽůĞ

of IL-17 in atherosclerosis. Cell Immunol. ϮϬϭϱ͖Ϯϵϳ;ϭͿ͗ϯϯͲϯϵ͘

ϭϮ͘ ZƵĚǁĂůĞŝƚD͕ǀĂŶĚĞƌ,ĞŝũĚĞ͕>ĂŶĚĞǁĞZ ĞƚĂů͘dŚĞƐƐĞƐƐŵĞŶƚŽĨ^ƉŽŶĚLJůŽƌƚŚƌŝƟƐ /ŶƚĞƌŶĂƟŽŶĂů^ŽĐŝĞƚLJĐůĂƐƐŝĮĐĂƟŽŶĐƌŝƚĞƌŝĂ ĨŽƌƉĞƌŝƉŚĞƌĂůƐƉŽŶĚLJůŽĂƌƚŚƌŝƟƐĂŶĚĨŽƌ ƐƉŽŶĚLJůŽĂƌƚŚƌŝƟƐŝŶŐĞŶĞƌĂů͘Ann Rheum Dis. ϮϬϭϭ͖ϳϬ;ϭͿ͗ϮϱͲϯϭ͘ ϭϯ͘ ǀĂŶDĞŶƐ>͕DĞŶĞŐĂƫ^͘ĞƚĂů͘īĞĐƚƐŽĨ ĂŶƟͲ/>ϭϳůŽĐŬĂĚĞǁŝƚŚƐĞĐƵŬŝŶƵŵĂďŽŶ ƐLJƐƚĞŵŝĐĂŶĚůŽĐĂůŝŵŵƵŶĞƌĞƐƉŽŶƐĞƐ͗Ă ŵĞĐŚĂŶŝƐŵͲŽĨͲĂĐƟŽŶƐƚƵĚLJŝŶƉĞƌŝƉŚĞƌĂů ƐƉŽŶĚLJůŽĂƌƚŚƌŝƟƐ΀ĂďƐƚƌĂĐƚ΁͘ZͬZ,WŶŶƵ-ĂůDĞĞƟŶŐ͕ϯͲϴEŽǀĞŵďĞƌϮϬϭϳ͕^ĂŶŝĞŐŽ͕ ĂůŝĨŽƌŶŝĂ͖ďƐƚƌĂĐƚŶƵŵďĞƌ͗ϮϴϬϭ͘ ϭϰ͘ dƵƌŝŶĂD͕ZĂŵŝƌŽ^͕ĂĞƚĞŶ>ĞƚĂů͘ƉƐLJ-ĐŚŽŵĞƚƌŝĐĂŶĂůLJƐŝƐŽĨŽƵƚĐŽŵĞŵĞĂƐƵƌĞƐŝŶ ƉĞƌŝƉŚĞƌĂůƐƉŽŶĚLJůŽĂƌƚŚƌŝƟƐ͘Ann Rheum Dis. ϮϬϭϲ͖ϳϱ;ϳͿ͗ϭϯϬϮͲϭϯϬϳ͘ ϭϱ͘ ZŽƵďŝůůĞ͕ZŝĐŚĞƌs͕^ƚĂƌŶŝŶŽdĞƚĂů͘dŚĞ ĞīĞĐƚƐŽĨƚƵŵŽƵƌŶĞĐƌŽƐŝƐĨĂĐƚŽƌŝŶŚŝďŝƚŽƌƐ͕ ŵĞƚŚŽƚƌĞdžĂƚĞ͕ŶŽŶͲƐƚĞƌŽŝĚĂůĂŶƟͲŝŶŇĂŵŵĂ- ƚŽƌLJĚƌƵŐƐĂŶĚĐŽƌƟĐŽƐƚĞƌŽŝĚƐŽŶĐĂƌĚŝ-ŽǀĂƐĐƵůĂƌĞǀĞŶƚƐŝŶƌŚĞƵŵĂƚŽŝĚĂƌƚŚƌŝƟƐ͕ ƉƐŽƌŝĂƐŝƐĂŶĚƉƐŽƌŝĂƟĐĂƌƚŚƌŝƟƐ͗ĂƐLJƐƚĞŵĂƟĐ ƌĞǀŝĞǁĂŶĚŵĞƚĂͲĂŶĂůLJƐŝƐ͘Ann Rheum Dis. ϮϬϭϱ͖ϳϰ;ϯͿ͗ϰϴϬͲϰϴϵ͘ ϭϲ͘ ĚĞƌ>͕:ŽƐŚŝ͕ĞLJ<ĞƚĂů͘ƐƐŽĐŝĂƟŽŶŽĨ dƵŵŽƌEĞĐƌŽƐŝƐ&ĂĐƚŽƌ/ŶŚŝďŝƚŽƌdƌĞĂƚŵĞŶƚ tŝƚŚZĞĚƵĐĞĚ/ŶĚŝĐĞƐŽĨ^ƵďĐůŝŶŝĐĂůƚŚĞƌŽ-ƐĐůĞƌŽƐŝƐŝŶWĂƟĞŶƚƐtŝƚŚWƐŽƌŝĂƟĐŝƐĞĂƐĞ͘ ƌƚŚƌŝƟƐZĞƵŵĂƚŽů͘ϮϬϭϴ͖ϳϬ;ϯͿ͗ϰϬϴͲϰϭϲ ϭϳ͘ DĂŬŝͲWĞƚĂũĂ<D͕ůŬŚĂǁĂĚD͕ŚĞƌŝLJĂŶ:Ğƚ Ăů͘ŶƟͲƚƵŵŽƌŶĞĐƌŽƐŝƐĨĂĐƚŽƌͲĂůƉŚĂƚŚĞƌĂƉLJ ƌĞĚƵĐĞƐĂŽƌƟĐŝŶŇĂŵŵĂƟŽŶĂŶĚƐƟīŶĞƐƐŝŶ ƉĂƟĞŶƚƐǁŝƚŚƌŚĞƵŵĂƚŽŝĚĂƌƚŚƌŝƟƐ͘Circula-ƟŽŶ͘ϮϬϭϮ͖ϭϮϲ;ϮϭͿ͗ϮϰϳϯͲϮϰϴϬ͘

(11)

ϭϴ͘ /ǁĂŬƵƌĂz͕EĂŬĂĞ^͕^ĂŝũŽ^ĞƚĂů͘dŚĞƌŽůĞƐŽĨ />ͲϭϳŝŶŝŶŇĂŵŵĂƚŽƌLJŝŵŵƵŶĞƌĞƐƉŽŶƐĞƐ and host defense against pathogens. Immunol

Rev. ϮϬϬϴ͖ϮϮϲ͗ϱϳͲϳϵ͘

ϭϵ͘ ,Žƚ͕>ĞŶŝĞĨs͕DŝŽƐƐĞĐW͘ŽŵďŝŶĂƟŽŶŽĨ/>Ͳ ϭϳĂŶĚdE&ĂůƉŚĂŝŶĚƵĐĞƐĂƉƌŽͲŝŶŇĂŵŵĂƚŽƌLJ͕ ƉƌŽͲĐŽĂŐƵůĂŶƚĂŶĚƉƌŽͲƚŚƌŽŵďŽƟĐƉŚĞŶŽƚLJƉĞ in human endothelial cells. Ann Rheum Dis. ϮϬϭϮ͖ϳϭ;ϱͿ͗ϳϲϴͲϳϳϲ͘ ϮϬ͘ 'ŝƐƚĞƌĂ͕ZŽďĞƌƚƐŽŶ<͕ŶĚĞƌƐƐŽŶ:ĞƚĂů͘ dƌĂŶƐĨŽƌŵŝŶŐŐƌŽǁƚŚĨĂĐƚŽƌͲďĞƚĂƐŝŐŶĂůŝŶŐ ŝŶdĐĞůůƐƉƌŽŵŽƚĞƐƐƚĂďŝůŝnjĂƟŽŶŽĨĂƚŚĞƌ- ŽƐĐůĞƌŽƟĐƉůĂƋƵĞƐƚŚƌŽƵŐŚĂŶŝŶƚĞƌůĞƵ-ŬŝŶͲϭϳͲĚĞƉĞŶĚĞŶƚƉĂƚŚǁĂLJ͘^ĐŝdƌĂŶƐůDĞĚ͘ ϮϬϭϯ͖ϱ;ϭϵϲͿ͗ϭϵϲƌĂϭϬϬ͘ Ϯϭ͘ dĂůĞď^͕ZŽŵĂŝŶD͕ZĂŵŬŚĞůĂǁŽŶĞƚĂů͘>ŽƐƐ ŽĨ^K^ϯĞdžƉƌĞƐƐŝŽŶŝŶdĐĞůůƐƌĞǀĞĂůƐĂƌĞŐƵ- ůĂƚŽƌLJƌŽůĞĨŽƌŝŶƚĞƌůĞƵŬŝŶͲϭϳŝŶĂƚŚĞƌŽƐĐůĞƌŽ-sis. :džƉDĞĚ͘ϮϬϬϵ͖ϮϬϲ;ϭϬͿ͗ϮϬϲϳͲϮϬϳϳ͘

(12)

9

ĂƐĞůŝŶĞĐŚĂƌ ĂĐƚ ĞƌŝƐ ƟĐƐďLJŐƌ ŽƵƉďĂƐĞĚŽŶƚŚĞ ZϱϬƌ ĞƐƉŽŶƐĞĐƌ ŝƚ ĞƌŝĂ Z ĞƐƉŽŶĚĞƌ Ɛ ; ZϱϬĂĐŚŝĞ ǀĞĚͿ EŽŶͲƌ ĞƐƉŽŶĚĞƌ Ɛ ; ZϱϬŶŽƚ ĂĐŚŝĞ ǀĞĚͿ ŚĂƌ ĂĐƚ ĞƌŝƐ ƟĐƐ ĂƐĞůŝŶĞ;ŶсϴͿ W Ž Ɛƚ Ͳƚƌ ĞĂ ƚŵĞŶ ƚ;ŶсϴͿ Wǀ ĂůƵĞ ĂƐĞůŝŶ Ğ;ŶсϴͿ W Ž Ɛƚ Ͳƚƌ ĞĂ ƚŵĞŶ ƚ;ŶсϴͿ Wǀ ĂůƵĞ 'ĞŶĚĞƌ ͕ŵĞŶͬǁ ŽŵĞŶ ϳͬϭ Ŷͬ Ă Ŷ ͬĂ ϱͬϯ Ŷͬ Ă Ŷ ͬĂ Ő Ğ͕LJ ĞĂƌ Ɛ ϰϰцϭϭ Ŷͬ Ă Ŷ ͬĂ ϰϱцϭϰ Ŷͬ Ă Ŷ ͬĂ D/͕ŬŐ ͬŵ 2 Ϯϵцϰ Ŷͬ Ă Ŷ ͬĂ Ϯϲцϱ Ŷͬ Ă Ŷ ͬĂ VA Spain sc or e 31[24-58] 5.5[1-18] 0.012 44[38-51] 33[8-47] 0.183 SJC 2.5[1.3-4] 0[0-0.8] 0.011 3[1.5-4.8] 1[0-1] 0.016 d:  4.5[1.25-10.25] 0[0-1.75] 0.012 7[6-9] 2[0-4.75] 0.024 ZW ͕ŵŐ ͬ> 4.6[1.5-16.6] 1.4[0.6-6.3] 0.050 2.2[1.0-7.5] 2.0[0.9-3.9] 0.263 ^͕ŵŵͬh 13.5[6-31.50] 7[3-14.8] 0.237 7.5[2-30.8] 5.5[2-24] 0.168 >>ĐŚŽůĞƐ ƚĞ ƌŽů͕ŵŵŽůͬ> ϯ͘ϭцϬ͘ϵ ϯ͘ϳцϭ͘Ϯ 0.094 ϯ͘ϰцϬ͘ϴ ϯ͘ϰцϬ͘ϵ 0.948 Ăƌ Ğ Ŷ͕ ŵĞĂŶц^ Žƌ ŵĞĚŝĂŶ ΀/YZ΁ ĨŽƌ ŶŽŶͲŶŽƌŵĂůůLJ ĚŝƐ ƚƌŝďƵ ƚĞĚ ĚĂ ƚĂ͘ D/͗ ďŽĚLJ ŵĂƐƐ ŝŶĚĞ dž͖ ZW͗ ͲƌĞĂĐƟǀĞ ƉƌŽƚ ĞŝŶ͖ ^ :͗ ǁŽůůĞŶ ũŽ ŝŶ ƚ ĐŽƵŶ ƚ͖ d :͗ ƚĞŶĚĞƌ ũŽŝŶ ƚ ĐŽƵŶ ƚ͖ s ^͗

Referenties

GERELATEERDE DOCUMENTEN

Although it exists on the edges of several fields – performance art, rock concert and music theatre – Homeland also intervenes in the opera world and questions it

To confirm how texts used in postoperas are dramatic texts I use an argument by Patrice Pavis: “(...) any ordinary text can become dramatic as soon as it is

singing a capella, without instrumental accompaniment or pre-recorded sound, without any technological interventions to the voices; 2) Voices of three tenors singing

Glass synchronises the singing voice and instrumental music to the film image of the speaking body, and he achieves an unusual operatic result that relies on the

The AOEN mask used in the current manuscript was generated from data collected on an independent sample of 35 participants who underwent an action execution and action observation

If one takes an overall view, the environmental advantage of lower direct material inputs in the nanoparticulate solar cells considered here, is counterbalanced by relatively

The photophysics of solution processable semiconductors for applications in optoelectronic devices..

Our search strategy included a combination of three general search terms: chemical terms (PCB, polychlorinated biphenyl, OH-PCB, hydroxylated polychlorinated biphenyl,